Nurix Therapeutics, Inc. (NRIX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.14+3.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NRIX
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(3.1) + peer(0.2*0.0) + term(0.0) → 1.09% (capped ±15.0)
in 32 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On July 9, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended May 31, 2026. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On April 8, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended February 28, 2026. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…
Results of Operations and Financial Condition. On January 28, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter and year ended November 30, 2025. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…
Results of Operations and Financial Condition. On October 9, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended August 31, 2025. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…
Results of Operations and Financial Condition. On July 9, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended May 31, 2025. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…
Results of Operations and Financial Condition. On April 8, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended February 28, 2025. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Condition. On January 28, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended November 30, 2024. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…
Results of Operations and Financial Condition. On January 13, 2025, Nurix Therapeutics, Inc. (the “Company”) will present an investor presentation at the 43rd Annual J.P. Morgan Healthcare Conference (the “JPM Conference”), which reports the preliminary, unaudited amount of the Company’s cash, cash equivalents and marketable securities position as of November 30, 2024, as $609.6 million, and reports that, based on its current operating plan, the Company expects that it will be able to fund it…
Results of Operations and Financial Condition. On October 11, 2024, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended August 31, 2024. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…
Results of Operations and Financial Condition. On July 11, 2024, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended May 31, 2024. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
Results of Operations and Financial Condition. On April 10, 2024, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended February 29, 2024. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…
Results of Operations and Financial Condition. On February 15, 2024, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended November 30, 2023. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…